HK Stock Market Move | SIHUAN PHARM (00460) rose by over 6% after the gain. Expected annual revenue growth rate exceeds 30% and net profit is expected to be no less than 1.5 billion yuan.

SIHUAN PHARM (00460) rose by more than 6% after the market closed, and as of the time of this report, it had increased by 2.99% to HK$1.72, with a turnover of HK$51.1413 million. On the news front, SIHUAN PHARM announced that the group expects to achieve revenue of no less than 2.5 billion yuan for the year ending December 31, 2025, representing a growth rate of over 30% compared to the same period last year, and a net profit of no less than 150 million yuan. The performance growth is mainly attributed to the high-speed growth of the group's medical beauty business, which achieved revenue of over 1.4 billion yuan and a branch profit of over 700 million yuan during the year, both of which have increased by over 90% compared to the previous year, becoming the group's largest revenue and profit pillar, significantly boosting overall performance; the innovative drug business has entered the harvest period, significantly improving the group's profit structure; the company's financial situation is stable, with sufficient cash on hand, multiple rounds of share buybacks have been implemented and the Xuanzhu Biology spin-off listing has been completed, optimizing the group's financial structure and driving a breakthrough in profit.